VANCOUVER, BC, Feb. 17, 2023 /CNW/ - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the "Company" or "WELL"), a company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, announced today that it has established a combined goal of donating $50,000 to support the Red Cross in its efforts to support the millions of Turkish and Syrian citizens who have been impacted by the earthquake. WELL will be matching the first $15,000 of donations.
As of February 16th, over 40,000 people have lost their lives and thousands are still missing due to the earthquakes that took place on February 6, 2023. The Red Cross Red Crescent is working to deliver emergency relief and get help to those impacted by the earthquakes as quickly as possible.
WELL's CEO and members of the senior management team will be contributing to this donation appeal and have invited the Company's entire network of employees, consultants, friends, family, shareholders, vendors, healthcare providers and patients to also donate to this cause.
Shane Sabatino, WELL's Chief People Officer said, "The humanitarian catastrophe in Türkiye and Syria is heartbreaking. WELL Health Technologies stands in solidarity with all those impacted by these devastating earthquakes and supports the Red Cross' much-needed humanitarian efforts. Our hearts are with all of those impacted by this disaster and on behalf of WELL, I would like to extend my deepest gratitude for everyone's donations to this cause."
Furthermore, WELL recognizes that this crisis may also be impacting its own WELL team members, especially ones with family and friends in Türkiye and Syria. So, in partnership with Focus Mental Wellness ("Focus"), WELL is providing fully subsidized access to therapy with a licensed practitioner for its employees, healthcare providers, consultants, and their families in Canada. Focus is a virtual online therapy clinic that provides secure online video, phone and text therapy for individuals and their families struggling with mental health issues.
Please join WELL in providing emergency donation support to the millions of Turkish and Syrian people affected by the earthquakes. To donate, go to Red Cross Canada – Donors from Canada or International can donate at: https://www.redcross.ca/turkiyesyriaappeal/WELLHealth
Donors from the United States can donate at: https://www.redcross.org/donate/cm/wellhealth-emp.html/
WELL HEALTH TECHNOLOGIES CORP.
Per: "Hamed Shahbazi"
Hamed Shahbazi
Chairman, Chief Executive Officer and Director
WELL is a practitioner focused digital healthcare company whose overarching objective is to positively impact health outcomes to empower and support healthcare practitioners and their patients. WELL has built an innovative practitioner enablement platform that includes comprehensive end-to-end practice management tools inclusive of virtual care and digital patient engagement capabilities as well as Electronic Medical Records (EMR), Revenue Cycle Management (RCM) and data protection services. WELL uses this platform to power healthcare practitioners both inside and outside of WELL's own omni-channel patient services offerings. As such, WELL owns and operates Canada's largest network of outpatient medical clinics serving primary and specialized healthcare services and is the provider of a leading multi-national, multi-disciplinary telehealth and EMR offering. WELL is publicly traded on the Toronto Stock Exchange under the symbol "WELL" and trades on the OTCQX under the symbol "WHTCF". To learn more about the Company, please visit: www.WELL.company.
Last Trade: | C$7.04 |
Daily Change: | 0.04 0.57 |
Daily Volume: | 1,798,209 |
Market Cap: | C$1.750B |
October 09, 2024 October 01, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB